Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Inclusion Criteria: * Pts w confirmed GBM, GS, AA, AO \& AOA are presenting in 1st, 2nd/3rd recurrence/relapse * Pts without tumor biopsy \<1 wk/surgical resection \<2 wks prior to starting study drug * For stratum of non-EIAED pts, each pts off all enzyme inducing anticonvulsants for \>2 wks prior to starting study drug * Pts should be on non-increasing dose of steroids for \>7 days prior to obtaining baseline Gd-MRI of brain * Pts should be on non-increasing dose of steroids for \>7 days prior to starting study drug * Pts w previous implantation of Gliadel may be eligible after discussion between investigator \& sponsor * Multifocal disease is eligible * Age \>18 yrs * KPS \>70 * Hematology: ANC\>1.5 x 10\^9/L, Hgb\>9 g/dL, Platelets\>100 x 10\^9/L * Biochemistry: K≥ LLN/correctable w supplement, Total Ca≥ LLN/correctable w supplement, Mg≥ LLN/correctable w supplement, P≥ LLN/correctable w supplement, AST/SGOT \& ALT/SGPT \<2.5 x ULN, Serum bilirubin \<1.5 x ULN, Serum creatinine \<1.5 x ULN/measured 24hr CrCl\<0 mL/min/1.73m2, \& Cholesterol≤ 00 mg/dL \& triglyceride≤2.5 ULN * Life expectancy ≥12wks * Written informed consent obtained prior to any screening procedures Exclusion Criteria: * Pts w any peripheral neuropathy ≥CTCAE gr2 * Pts w unresolved diarrhea ≥CTCAE gr2 * History of impaired cardiac function * Obligate use of cardiac pacemaker, Congenital long QT syndrome, History or presence of ventricular or atrial tachyarrhythmias, Clinically significant resting bradycardia , Right bundle branch block + left anterior hemiblock * Other clinically significant cardiac diseases * Uncontrolled Db * Active or uncontrolled infection requiring intravenous antibiotics * Impairment of GI function/GI disease that may significantly alter absorption of Gleevec, hydroxyurea and/or RAD001 * Acute/chronic liver/renal disease * Other concurrent severe and/or uncontrolled medical condition that could cause unacceptable safety risks/compromise compliance w protocol * Treatment w any hematopoietic colony-stimulating factor ≤2wks prior to starting study drug. Erythropoietin is allowed * Pts w history of CHF/arrhythmias who are receiving treatment w digoxin/verapamil, \& treatment cannot be discontinued/switched to different drug prior to starting study drug * Pts taking warfarin sodium * Pts received treatment w PDGF/mTOR directed therapies * Pts received chemo ≤ 4wks prior to starting study drug/have not recovered from side effects of such therapy * Pts received immunotherapy ≤2 wks prior to starting study drug/have not recovered from side effects of such therapy * Pts received investigational drugs ≤4 wks prior to starting study drug/have not recovered from side effects of such therapy * Pts received XRT ≤4 wks prior to starting study drug/have not recovered from side effects of such therapy * Pts undergone major non-CNS surgery ≤2 wks prior to starting study drug/pts have not recovered from side effects of such therapy * Cardiac pacemaker, Ferromagnetic metal implants other than those approved as safe for use in MR scanners, Claustrophobia, Obesity * Female pts are pregnant/breast feeding,/adults of reproductive potential not employing effective method of birth control. Barrier contraceptives must be used throughout trial in both sexes. Oral, implantable/injectable contraceptives may be affected by cytochrome P450 interactions, \& are therefore not considered effective for study. Women of childbearing potential have negative serum pregnancy test 48hrs prior to administration of Gleevec, hydroxyurea and/or RAD001. * Known diagnosis of HIV infection * Pts w history of another primary malignancy that is currently clinically significant/currently requires active intervention * Pts unwilling to/unable to comply w protocol